Evidence map›Paper›PMID 42794692›Full record

Observational studyInternational journal of molecular sciences2026

Impaired α-Granule Secretion Dominates Longitudinal Agonist-Induced Platelet Dysfunction in Gaucher Disease.

Shoshana Revel-Vilk, Ari Zimran, Tama Dinur, Dafna Frydman, Elena Shulman, Emmanuel Benayoun, Eti Broide, Mira Naamad, Nechama Koren, Michal Saltsman

Abstract readObservational Study
In one paragraph

Observational study in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Shoshana Revel-VilkGaucher Unit, The Eisenberg R&D Authority, Shaare Zedek Medical Center, Jerusalem 9103102, Israel.ORCID 0000-0001-9151-0337
Ari ZimranGaucher Unit, The Eisenberg R&D Authority, Shaare Zedek Medical Center, Jerusalem 9103102, Israel.ORCID 0000-0003-0077-8608
Tama DinurGaucher Unit, The Eisenberg R&D Authority, Shaare Zedek Medical Center, Jerusalem 9103102, Israel.
Dafna FrydmanGaucher Unit, The Eisenberg R&D Authority, Shaare Zedek Medical Center, Jerusalem 9103102, Israel.ORCID 0009-0007-3398-7584
Elena ShulmanGaucher Unit, The Eisenberg R&D Authority, Shaare Zedek Medical Center, Jerusalem 9103102, Israel.ORCID 0009-0006-2088-0422
Emmanuel BenayounFlow Cytometry Unit, Shaare Zedek Medical Center, Jerusalem 9103102, Israel.
Eti BroideFlow Cytometry Unit, Shaare Zedek Medical Center, Jerusalem 9103102, Israel.
Mira NaamadFlow Cytometry Unit, Shaare Zedek Medical Center, Jerusalem 9103102, Israel.
Nechama KorenFlow Cytometry Unit, Shaare Zedek Medical Center, Jerusalem 9103102, Israel.
Michal SaltsmanFlow Cytometry Unit, Shaare Zedek Medical Center, Jerusalem 9103102, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bleeding in Gaucher disease (GD) is not fully explained by thrombocytopenia and coagulation disorders. Previous studies have shown impaired agonist-induced cluster of differentiation (CD) 62P (CD62P/P-selectin) responses, but their persistence over time is unknown. This retrospective longitudinal observational study characterized platelet activation and secretion responses over time and factors associated with persistent abnormalities. Whole-blood flow cytometry studies from 333 patients with GD with at least two assessments were analyzed. Platelet activation complex-1 (PAC1), CD62P, and CD63 responses were categorized longitudinally. Patients contributed 949 visits over a median follow-up of 2.3 years. Persistent CD62P abnormality was most frequent (92/333, 27.6%), compared with PAC1 (45/329, 13.7%) and CD63 (9/328, 2.7%). PAC1 abnormalities were more often dynamic, whereas CD62P abnormalities were frequent and persistent, most often involving thrombin receptor-activating peptide 6 (TRAP-6) and cross-linked collagen-related peptide (CRP-XL). Lower platelet count was independently associated with persistent CD62P abnormality, although approximately half of affected patients had platelet counts ≥150 × 10

Indexed as

Blood PlateletsGaucher DiseaseAdolescentAdultAgedChildFemaleHumansLongitudinal StudiesMaleMiddle AgedPlatelet ActivationPlatelet CountP-SelectinRetrospective StudiesTetraspanin 30P-SelectinTetraspanin 30agonist-induced platelet functionCD62Pflow cytometryGaucher diseaseplatelet activationP-selectinα-granule secretion

Identifiers

PMID42794692
PMCPMC13607744

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.